The complement inhibitors in COVID-19: future expectations

Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6480-6481. doi: 10.26355/eurrev_202006_21628.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Betacoronavirus
  • COVID-19
  • Complement Inactivating Agents*
  • Coronavirus Infections*
  • Humans
  • Motivation*
  • Pandemics*
  • Pneumonia, Viral*
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • eculizumab